Antimicrobial Activity of Actinomycetes Extracts Against Multidrug Resistant Staphylococcus aureus and Salmonella spp isolated from meat

Ahmed, Walaa Eldeen; Helal, Ihab; Zaky, Mahmoud; Abdulla, Hesham

doi:10.21608/ajbas.2022.122842.1090

Cited by 1 publication

(1 citation statement)

References 39 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this purpose, researchers have been putting intense efforts into finding rare actinomycetes, particularly those that are residing in novel niches. The search for actinomycetes has been conducted on various soils in a variety of geographical locations 5 . Many rare actinomycetes belonging to the genera Amycolatopsis , Nocardia , Pseudonocardia, and Micromonospora have been reported from such locations; therefore, attention has now been turned towards isolating them from plants 2 .…”

Section: Introductionmentioning

confidence: 99%

Multifunctional in vitro, in silico and DFT analyses on antimicrobial BagremycinA biosynthesized by Micromonospora chokoriensis CR3 from Hieracium canadense

Tanvir,

Ijaz,

Sajid

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Among the actinomycetes in the rare genera, Micromonospora is of great interest since it has been shown to produce novel therapeutic compounds. Particular emphasis is now on its isolation from plants since its population from soil has been extensively explored. The strain CR3 was isolated as an endophyte from the roots of Hieracium canadense, and it was identified as Micromonospora chokoriensis through 16S gene sequencing and phylogenetic analysis. The in-vitro analysis of its extract revealed it to be active against the clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and Candida tropicalis (15 mm). No bioactivity was observed against Gram-negative bacteria, Escherichia coli ATCC 25922, and Klebsiella pneumoniae ATCC 706003. The Micromonospora chokoriensis CR3 extract was also analyzed through the HPLC-DAD-UV–VIS resident database, and it gave a maximum match factor of 997.334 with the specialized metabolite BagremycinA (BagA). The in-silico analysis indicated that BagA strongly interacted with the active site residues of the sterol 14-α demethylase and thymidylate kinase enzymes, with the lowest binding energies of − 9.7 and − 8.3 kcal/mol, respectively. Furthermore, the normal mode analysis indicated that the interaction between these proteins and BagA was stable. The DFT quantum chemical properties depicted BagA to be reasonably reactive with a HOMO-LUMO gap of (ΔE) of 4.390 eV. BagA also passed the drug-likeness test with a synthetic accessibility score of 2.06, whereas Protox-II classified it as a class V toxicity compound with high LD50 of 2644 mg/kg. The current study reports an endophytic actinomycete, M. chokoriensis, associated with H. canadense producing the bioactive metabolite BagA with promising antimicrobial activity, which can be further modified and developed into a safe antimicrobial drug.

show abstract

Section: Introductionmentioning

confidence: 99%